Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 42 out of 100. Disparities

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

ADOD cases have steadily increased, with projections indicating continued growth by 2030. Aging and life expectancy are major contributors, with urban areas like Kantō and Kansai region experiencing higher prevalence than Tōhoku and Kyūshū. High fasting plasma glucose, obesity, and smoking are significant modifiable risk factors. The ARIMA model forecasts an ongoing upward trend, highlighting a rising public health challenge. Targeted policies, early interventions, and equitable health care access are vital to mitigating Japan's growing ADOD burden. HIGHLIGHTS: Alzheimer's disease and other dementias (ADOD) are rising in Japan due to an aging population. Key risk factors include high fasting plasma glucose, obesity, and smoking. Kantō and Kansai region have higher ADOD prevalence than other region ARIMA modeling predicts a continuous increase in ADOD cases through 2030. Targeted health care policies and preventive measures are crucial to mitigate the burden.

What this study adds

Evidence grade: Low

This study projects that Alzheimer's disease and other dementias will continue rising in Japan through 2030, with high fasting plasma glucose, obesity, and smoking as significant modifiable risk factors. It supports targeted policies and prevention efforts but does not test a treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Behera, D. K., Rahut, D. B., & Tripathy, S. (2025). Alzheimer's disease and dementia in Japan: Epidemiological trends, regional disparities, and future projections. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70444

Vancouver

Behera DK, Rahut DB, Tripathy S. Alzheimer's disease and dementia in Japan: Epidemiological trends, regional disparities, and future projections. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70444. PMID: 40631426.

BibTeX

@article{behera2025-40631426,
  author  = {Behera, Deepak Kumar and Rahut, Dil Bahadur and Tripathy, Snehasish},
  title   = {{Alzheimer's disease and dementia in Japan: Epidemiological trends, regional disparities, and future projections}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70444},
  pmid    = {40631426},
  url     = {https://doi.org/10.1002/alz.70444}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study projects that Alzheimer's disease and other dementias will continue rising in Japan through 2030, with high fasting plasma glucose, obesity, and smoking as significant modifiable risk factors. It supports targeted policies and prevention efforts but does not test a treatment or cure.

Study details

How this study scored 42/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 42 of 100.42 of 100 points earned58 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 17 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 5.7 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 10.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Snehasish Tripathy: h-index 10 (OpenAlex, whole career)
Institution's track record 0 / 3 Dr. D.Y. Patil Vidyapeeth, Pune: institution h-index 91 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40631426)
Free to read 2 / 2 Free to read
Total 42 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Disparities from nearby years

Also tagged “prevalence”

1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disparities

See all studies in Disparities →